Substance use disorders (SUDs) are a worldwide problem that contributes to the spread of HIV, hepatitis C, tuberculosis, criminal behavior, and other medical and psychosocial problems. Across societies, there is great diversity in capabilities to treat SUDs and even greater diversity regarding the capacity to conduct research on SUDs. Globally, demand for treatment exceeds capacity, and the gap is greatest in low-and middle-income countries (LMICs). 1 Only 20% of LMIC residents with mental, neurological, or substance abuse disorders receive treatment, but they constitute 80% of the global population needing treatment. 2 Societies have typically developed treatment capacity for SUDs in response to the crime associated with SUDs, including drug trafficking, or their medical/psychiatric sequelae, including infectious diseases. After treatment services are initiated, policy makers often want to gain knowledge about the nature and extent of drug use in their society, the populations affected, and the effectiveness of their treatments. As a result, there is expanding interest in the development of addiction research and evaluation capacity. In addition, many young professionals in countries with developing SUD services recognize that training in addiction research can be a pathway for career advancement. This training is also critical to support the large global investment in addressing infectious diseases, such as the human immunodeficiency virus (HIV) and tuberculosis, since injection drug use and addiction are a critical focus in such prevention and treatment programs of LMIC. With this background in mind, our focus in this article is to review the development of research capacity on tobacco, prescription medications, and illicit drugs in developing countries.
Surely, other work to promote international research on substance use-related issues predates and is contemporaneous to the National Institute on Drug Abuse (NIDA) programs described below. Researchers from Maudsley Institute, led by Griffith Edwards, M.D., and 3 others, led international research and research promotion efforts as early as the 1970s. 3 Research supported by NIAAA, led by Tom Babor, Ph.D., and others has created research and research capacity in the area of alcohol use and misuse. 4 Additionally, research on a variety of SUDs has been funded by the World Health Organization (WHO) and the U.S. Department of State. We have chosen to limit the scope of this paper to a review of the programs of research and research capacity-building efforts on drug use, in order to explore the themes of extant work in this topical area as well as research efforts being built in a variety of societies around the world.
NIDA International Research and Training Program Mechanisms to Promote Drug Abuse

Research
Since 1990, NIDA, which is part of the National Institutes of Health, has addressed the need for building addiction research and treatment capacity internationally through research training fellowships and professional development activities. 5 Postdoctoral researchers, midcareer professionals, and senior scientists have received addiction training and conducted mentored research on addiction topics ranging from basic science to epidemiology, prevention, treatment, medical and social consequences, and policy. The impact of NIDA-supported science and these training programs has influenced addiction treatment policies and practices in many parts of the world. said their fellowship helped them obtain the job and that the new job represented a change in career goals. Since completing their training, nearly half (47%) of the fellows reported having conducted research, more than a third (35.9%) reported continuing collaborations with a U.S.
partner, and one-fifth (20%) had enrolled in an academic program. At the 12-and 36-month follow-up, 17% had received a research grant, 38% were collaborating with U.S. colleagues, and 17% were collaborating with other fellows. Fellows also have contributed to the evidence base: 29% reported publishing research results in a peerreviewed journal, and 60% reported making a presentation at a scientific conference. 8 Three former NIDA International fellows edit journals in Australia, Brazil, and Nigeria, and former fellows have published more than 1,000 articles in peer-reviewed journals. Former fellows also shape drug policies in their own countries and currently hold government positions in Bangladesh, Brazil, India, Indonesia, Iraq, Israel, Mexico, Peru, Tanzania, and Uruguay.
Developments in International Addiction Research Capacity
In addition to promoting and funding the training of international addiction researchers, NIDA has a number of mechanisms for funding research outside the United States. Currently, 
Substance Abuse Research Center (SARC) at Jazan University, Saudi Arabia
In 2011, the government of the Kingdom of Saudi Arabia granted Jazan University a 3-year award to establish a university-based organization to coordinate and fund SUD research throughout the Kingdom of Saudi Arabia. This 3-year award was made with the intention to: (1) develop a set of research priorities to address major SUD problems in the Kingdom; (2) establish a research funding infrastructure at Jazan University to support a systematic peer review of research proposals and a competitive award process; (3) create a grants management capacity to oversee the quality assurance of research awards and ensure appropriate fund management; (4) promote greater attention to addiction research at Jazan University; and (5) develop an intramural addiction research capability at Jazan University initially focusing on issues in Southern Saudi Arabia. Representatives of NIDA and NIDA-funded researchers have been active in developing the agenda for research and advising on the grant application and grant review process.
During the first three years of operation, the resulting Substance Abuse Research Center (SARC) established as its priorities research on: khat (a major concern in the Jazan region, Yemen, and East Africa); Captagon (a tablet form of methamphetamine/caffeine that is the most 8 widely used illicit drug in Saudi Arabia); and smoking tobacco cigarettes and "shisha," a form of tobacco smoked in water pipes. Initial studies funded by SARC included an assessment of the extent of khat use in Southern Saudi Arabia [11] [12] [13] and reasons for stopping khat use. 14 Other projects were funded and completed on the dental consequences of khat use 15 and the neuropsychological functioning of chronic khat users. 16 Work from the first 3 years of funding of SARC has generated 13 peer-reviewed publications, with a number of others in press or under review. In 2013, the first annual conference on addiction research (with an emphasis on khat) was held in Jazan and included Saudi and international researchers. Plans are underway to increase funding for SARC and expand the research portfolio to include intervention and basic research as part of a broader portfolio of addiction research topics.
Building Global Addiction Research Capacity: Selected Examples
During the early years of NIDA's international efforts, much of the work was done in Subsequent trials demonstrated the efficacy of buprenorphine (BUP) to treat heroin-dependent injection drug users (IDUs) 19 and showed improved outcomes with the addition of behavioral drug and HIV risk reduction counseling. 20 More recent research has demonstrated the cost-effectiveness of BUP treatment for heroin dependence and compared the cost of treating heroin addiction with buprenorphine in Malaysia and 32 other countries. 21 As a result of this research and its resulting policy changes, by 2013 about 10,000 patients had enrolled in BUP maintenance administered by 380 specially trained general medical practitioners and more than 27,750 patients have been enrolled at 333 government-run methadone maintenance programs. 22 With this national scale-up of treatment for opioid dependence, the evolving community-based treatment system in Malaysia is conducting research to determine the role to be played by NGO advocacy organizations and the importance of establishing community connections with local law enforcement, political leaders, and related officials, whose implicit and explicit approval is needed to locate and operate local treatment and related addiction support services. In addition, ongoing studies are conducting cognitive, neuropsychological, and epidemiological assessments of individuals who abuse amphetaminetype stimulants (ATS) and heroin, and testing the efficacy of ATS treatment medications administered in conjunction with BUP maintenance therapy. NIDA-supported researchers have built an effective partnership that developed substance abuse treatment training programs for primary care providers, needle exchange programs, and scientific publications and presentations.
Their work helped improve the availability of HIV treatment for injection drug users and was instrumental in shifting Malaysian policy from incarceration of drug users to medical treatment.
Sub-Saharan Africa
In July 2010, the government of Tanzania announced that in an effort to control the country's IDU-related HIV epidemic, it would change long-standing drug policies and launch the 
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Among their findings were one of the first reports to identify HIV transmission via shared injection works among an African IDU population 28 and the first report of a novel practice-called "flashblood"-among female IDU sex workers in Dar es Salaam, in which they draw back a syringe full of blood immediately after injecting heroin and give that blood to a friend who injects it. 29, 30 Recognizing that high-risk practices related to drug use, particularly injection drug use, contribute to HIV transmission, the Tanzanian government sought support from PEPFAR to implement evidence-based interventions to prevent HIV among drug users. 
Brazil
In Brazil, cocaine use is the most significant public health problem posed by illicit drug use. 35, 36 Researchers from the University of Pennsylvania, together with Brazilian colleagues 
Russian Federation
The spread of injection drug use and HIV have been well documented in Russia. 40, 41 Russian addiction treatment programs focus almost entirely on inpatient detoxification and rehabilitation since Russian law prohibits methadone and other opioid agonist treatments.
However, naltrexone is approved in Russia, and the widespread use of inpatient detoxification makes it easy to initiate the medication during inpatient treatment. Following a NIDA/Pavlov State Medical University meeting in St. Petersburg in 1998, researchers from the University of Pennsylvania (Penn), Pavlov State Medical University, and the Leningrad Narcology Center developed a plan to study the efficacy of naltrexone for opioid (heroin) relapse prevention. Subsequently, with support from NIDA, a series of randomized 6-month trials of naltrexone were conducted. All were prospective, placebo-controlled, 6-month trials with follow-ups at 12 months and approved by the Pavlov and University of Pennsylvania IRBs. The primary outcome was remaining in treatment without relapsing. Secondary outcomes included ASI domains, HIV risk, psychiatric symptoms, and quality of life. A brief summary of their results follows:
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• A trial involving 52 patients showed that oral naltrexone was superior to placebo in preventing relapse. Results were that 12% of placebo patients remained in treatment and had not relapsed by Month 6, as compared to 44% of patients on oral naltrexone. 42 • A study involving 280 patients evaluated the addition of an SSRI to oral naltrexone and found that it did not significantly improve outcomes over naltrexone alone, but the superiority of naltrexone to placebo was replicated.
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• Findings from these studies provided the background for a study that led to the U.S. Food and Drug Administration (FDA) approval of extended-release naltrexone (Vivitrol®) for preventing relapse to opioid addiction. 44 The study, a randomized, placebo-controlled trial of extended release naltrexone funded by Alkermes, Inc., demonstrated the efficacy of extended-release naltrexone in reducing relapse to heroin use. As a result, extendedrelease naltrexone is now an approved medication in the United States for individuals that do not have access to agonist maintenance treatment or are not interested in it.
• At about the same time that the Alkermes study was underway, the Penn-Pavlov team was conducting a NIDA-funded study in which 306 participants were randomized to three groups (102/group) using: (1) a naltrexone implant that blocks opioid for 2-3 months (Prodetoxon®; http://www.prodetoxon.ru) + oral naltrexone placebo; (2) 50 mg oral naltrexone + placebo implant; or (3) double placebo. Results were that 58% of the implant patients remained in treatment for 6 months without relapsing as compared to 16% of the oral naltrexone patients and 12% of the double placebo group. No serious adverse events were observed in association with naltrexone treatment. 40, 41 and described naltrexone use in Russia. [48] [49] [50] These studies have provided Russian investigators experience in conducting prospective randomized trials using NIH standards and technologies and point to the importance of integrating treatment for substance use disorders, primary care, and HIV. As a consequence, an academic course on integrated treatment has been approved by the Ministry of Health for use in postgraduate training programs throughout the Russian Federation.
Other research has supported the collaboration between non-governmental organizations with several government institutions of the Russian Federation to develop and implement model programs to provide access to health services for opioid dependent individuals, including those living with HIV. 51 In an initial research effort, partnership agreements provided the basis for a 
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In the course of this study, a NIDA supplement funded a pilot study of "Life Steps," an 16 HIV medication adherence intervention developed by Safren and colleagues, 54, 55 with an additional 25 patients. Focus groups were conducted in Kiev to determine modifications needed to make Life Steps applicable to Ukrainian culture, and Kiev research staff was trained in the modified intervention. Research in Ukraine is addressing improving engagement in substance abuse treatment, particularly methadone treatment, as well as adherence to medication treatment regimens for people living with HIV and who inject drugs.
Republic of Georgia
Two researchers from the Republic of Georgia (a Humphrey fellow and a NIDA CTN fellow) spent part, or all of their fellowships at the Penn/VA Addiction Treatment and Research Center.
Buprenorphine injecting was a significant problem in the Republic of Georgia and the Penn/Georgia team was awarded a R21 to study the efficacy of buprenorphine/naloxone versus methadone for opioid-addicted patients in Tbilisi. Patients were randomized (40/group) to daily methadone or daily buprenorphine/naloxonefor 12 weeks. Results showed very little drug use during treatment with both medications. After study medication ended, drug use remained low for patients who continued in treatment in the methadone or buprenorphine/naloxone programs in Tbilisi, but increased use was found for those that did not continue treatment.
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Iceland
Amphetamine use is a significant problem in Iceland. 58 A study in Sweden reported that naltrexone might be useful for treating amphetamine dependence. 59 To extend the Swedish finding, a NIDA-funded study led by researchers at Penn and the SAA-National Center of Addiction Medicine and Vogur Hospital in Reykjavik 58 was conducted in which 100 amphetamine-dependent participants were randomized to a 6-month course of extended-release naltrexone or placebo, each with drug counseling. The primary outcome was proportion of amphetamine-negative urine tests during weeks 1-24 of outpatient treatment. Results showed marked improvements, with very little drug use among the approximately 50% of patients who remained in treatment. However, there was no evidence of medication effect. These findings were presented at the 2013 College on Problems of Drug Dependence and a paper describing them is being prepared.
Central Asian Republics
Injection drug use has been described as the main driver of the regional HIV epidemic in the Central Asian Republics. NIDA-funded research has recently provided data that expands the driver to sexual transmission through female sex workers who inject drugs. • MMT is a highly effective treatment, but in Vietnam (and many other places) it is delivered from specially licensed clinics with census limits, and the clinics are generally only located in large cities. As a result, access to methadone treatment is seriously limited. Buprenorphine/naloxone is a partial agonist approved in many countries for the treatment of opiate addiction and its use has the potential to expand access to treatment. 
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The many new international researchers and research teams are building research capacity and adding to the knowledge about addiction in cultures where addiction has not been previously studied. This information will be invaluable in the development of effective prevention, care, and treatment services that meet the needs of policy makers, public health leaders, and most important, patients with substance-related and addiction disorders around the world.
